Fin @SEIMC_ 2025, como despedida los 10 trabajos
Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis: The BLING III Randomized Clinical Trial.
Mentions
Extended reach
Total likes
Video views
Mentions per month
Jun 2024 – Sep 2025Where it's discussed
-
X / Twitter196 posts
-
News27 articles
-
YouTube11 videos
-
Blogs5 articles
-
Bluesky4 posts
-
Facebook4 posts
-
Reddit2 posts
AI synopsis
What people are saying
The overall tone demonstrates a neutral recognition of the study's key conclusion—no significant difference in mortality—while some posts explore secondary outcomes and methodological details. Words like 'out' and references to conferences like #CCR24 and @JAMA_current contribute to a tone of dissemination and mild interest, with some participation indicating genuine curiosity but limited deep debate.
Most discussions acknowledge the study's findings that continuous versus intermittent infusion did not significantly affect mortality, reflecting cautious acceptance of the results.
Posts show moderate curiosity, with many summarizing key points and referencing the trial, but few deeply analyze implications.
Several discussions include references to the trial details, methodology, or related conferences, indicating active engagement, though not highly critical or profound.
The widespread sharing and discussion at conferences and in prominent medical circles suggest the study has some influence, but the limited later consequences imply a moderate impact.
Abstract in brief
- A study investigated if continuous infusion of β-lactam antibiotics reduces death risk in critically ill sepsis patients, comparing this method to intermittent infusion.
- Conducted in 104 ICUs across several countries from 2018 to 2023, the trial involved over 7,200 participants receiving either piperacillin-tazobactam or meropenem.
- Results showed a slight decrease in 90-day mortality for continuous infusion (24.9%) versus intermittent infusion (26.8%), but the difference was not statistically significant (-1.9% difference).
Top posts
Most liked on X and Bluesky敗血症に抗菌薬の間欠vs持続 10.1001/jama.2024.9779 過去に複数の間欠vs持続研究あり 今回過去最大規模RCT BLING III P: 重症敗血症 I: β-L (PIPC/TAZ or MEPM)持続 C: 間欠 O: 90死亡、治癒 結果:死亡有意差なし、持続で臨床的治癒率が高い これまでの試験を統合したメタ解析を見たいです https://t.co/xMuioVW8Gt
BLING III: In critically ill patients with sepsis, continuous vs intermittent β-lactam antibiotic infusions did not significantly reduce 90-day mortality. https://t.co/s2wdF1Qg2b https://t.co/luhusWZ7fJ
BLING III is out!
Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis https://t.co/ByNyXaFpOe
1/5 Most influential 2024 #abxstewardship papers presented by @tinymuscles at #IDWeek2024: Ongoing evidence supporting prolonged/continuous infusion of beta-lactam abx, BUT higher risk of catheter complications & abx side effects. https://t.co/9LXLEmzfjB, https://t.co/CyNyA2TdtA
All mentions
2024 Update on Long COVID Classification and Symptoms
Long COVID is now defined as a heterogeneous infection-associated chronic condition present for at least 3 months after SARS-CoV-2 infection. Dr. Leora Horwitz discusses the latest updates on the RECOVER-Adult Long…
Key Studies in Nephrology and Hypertension for 2024
In the first part of our internal medicine annual review 2024, key nephrological and hypertensiological studies are presented, including an analysis of hypertension risk and kidney function in living kidney donors. This…
Updates to the Declaration of Helsinki Address New Ethical Challenges
The Declaration of Helsinki, developed in 1964, has been updated for 2024. Dr. Jack S Resneck Jr discusses the revisions with JAMA Editor in Chief Kirsten Bibbins-Domingo, focusing on evolving ethical considerations in…
Trauma Oxygen Strategies: Restrictive vs Liberal Approaches in Clinical Trials
AcademyHealth CEO Aaron Carroll shares highlights from the 2024 Annual Research Meeting, discussing key findings from the TRAUMOX2 trial which compared restrictive versus liberal oxygen strategies in trauma patients…
Trends in Loneliness Among Older Adults from 2018 to 2024
Loneliness and social isolation rates among people age 50 to 80 have dropped back to prepandemic levels in 2024 after multiple years of elevation, but some groups still have very high rates. Dr. Preeti Malani discusses…
Evaluating Continuous Beta-Lactam Infusions in Critically Ill Sepsis Patients
Hosts Angela Huttner and Erin McCreary discuss the BLING3 trial comparing continuous versus intermittent beta-lactam antibiotic infusion in over 7,000 critically ill patients. The study explores potential mortality…
Comparison of Continuous vs Intermittent β-Lactam Antibiotic Infusions in Sepsis Patients
Joel M Dulhunty MD PhD and Jason A Roberts BPharm PhD discuss the BLING trial assessing whether continuous infusion of β-lactam antibiotics impacts mortality in sepsis or septic shock patients. The study analyzed over…
Impact of Child Health Policy on Pediatric Outcomes and Wellbeing
JAMA Pediatrics explores how policy influences child health using scientific evidence. The discussion features experts analyzing recent studies on policy issues affecting pediatric wellbeing.
Continuous vs Intermittent Antibiotic Infusions in Sepsis Treatment
This study compares continuous and intermittent lactam antibiotic infusions in critically ill sepsis patients to assess their impact on 90-day mortality. Results showed no significant difference between the two methods.
BALANCE Trial: Optimal Antibiotic Duration for Bacteremia Outcomes
In this episode, hosts Erin McCreary and Angela Huttner discuss the BALANCE trial, examining the effectiveness of a 7-day antibiotic treatment versus 14 days for uncomplicated gram-negative bacteremia. With insights…
Innovations and Insights in Infectious Disease Research 2024
Brett, Phil, and Martin reflect on the year's key papers, conferences, and developments in infectious disease research, including studies on antimicrobial resistance, infection control strategies, and clinical treatment…
RT @PittCCM: He presented: Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis: The BLING III R…
RT @infeccHRUmalaga: Fin @SEIMC_ 2025, como despedida los 10 trabajos
Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis https://t.co/kMCbxSR2l5
RT @infeccHRUmalaga: Fin @SEIMC_ 2025, como despedida los 10 trabajos
RT @infeccHRUmalaga: Fin @SEIMC_ 2025, como despedida los 10 trabajos
RT @infeccHRUmalaga: Fin @SEIMC_ 2025, como despedida los 10 trabajos
RT @infeccHRUmalaga: Fin @SEIMC_ 2025, como despedida los 10 trabajos
RT @infeccHRUmalaga: Fin @SEIMC_ 2025, como despedida los 10 trabajos
RT @infeccHRUmalaga: Fin @SEIMC_ 2025, como despedida los 10 trabajos
RT @infeccHRUmalaga: Fin @SEIMC_ 2025, como despedida los 10 trabajos
RT @infeccHRUmalaga: Fin @SEIMC_ 2025, como despedida los 10 trabajos
RT @infeccHRUmalaga: Fin @SEIMC_ 2025, como despedida los 10 trabajos
RT @infeccHRUmalaga: Fin @SEIMC_ 2025, como despedida los 10 trabajos
RT @infeccHRUmalaga: Fin @SEIMC_ 2025, como despedida los 10 trabajos
RT @infeccHRUmalaga: Fin @SEIMC_ 2025, como despedida los 10 trabajos
RT @infeccHRUmalaga: Fin @SEIMC_ 2025, como despedida los 10 trabajos
RT @infeccHRUmalaga: Fin @SEIMC_ 2025, como despedida los 10 trabajos
RT @infeccHRUmalaga: Fin @SEIMC_ 2025, como despedida los 10 trabajos
RT @infeccHRUmalaga: Fin @SEIMC_ 2025, como despedida los 10 trabajos
RT @infeccHRUmalaga: Fin @SEIMC_ 2025, como despedida los 10 trabajos
RT @infeccHRUmalaga: Fin @SEIMC_ 2025, como despedida los 10 trabajos
RT @infeccHRUmalaga: Fin @SEIMC_ 2025, como despedida los 10 trabajos
RT @infeccHRUmalaga: Fin @SEIMC_ 2025, como despedida los 10 trabajos
RT @infeccHRUmalaga: Fin @SEIMC_ 2025, como despedida los 10 trabajos
RT @infeccHRUmalaga: Fin @SEIMC_ 2025, como despedida los 10 trabajos
RT @infeccHRUmalaga: Fin @SEIMC_ 2025, como despedida los 10 trabajos
RT @infeccHRUmalaga: Fin @SEIMC_ 2025, como despedida los 10 trabajos
RT @infeccHRUmalaga: Fin @SEIMC_ 2025, como despedida los 10 trabajos
RT @infeccHRUmalaga: Fin @SEIMC_ 2025, como despedida los 10 trabajos
RT @infeccHRUmalaga: Fin @SEIMC_ 2025, como despedida los 10 trabajos
RT @infeccHRUmalaga: Fin @SEIMC_ 2025, como despedida los 10 trabajos
RT @infeccHRUmalaga: Fin @SEIMC_ 2025, como despedida los 10 trabajos
RT @infeccHRUmalaga: Fin @SEIMC_ 2025, como despedida los 10 trabajos
RT @infeccHRUmalaga: Fin @SEIMC_ 2025, como despedida los 10 trabajos
RT @infeccHRUmalaga: Fin @SEIMC_ 2025, como despedida los 10 trabajos
RT @infeccHRUmalaga: Fin @SEIMC_ 2025, como despedida los 10 trabajos
RT @infeccHRUmalaga: Fin @SEIMC_ 2025, como despedida los 10 trabajos
RT @infeccHRUmalaga: Fin @SEIMC_ 2025, como despedida los 10 trabajos
RT @infeccHRUmalaga: Fin @SEIMC_ 2025, como despedida los 10 trabajos
RT @infeccHRUmalaga: Fin @SEIMC_ 2025, como despedida los 10 trabajos
RT @infeccHRUmalaga: Fin @SEIMC_ 2025, como despedida los 10 trabajos
RT @infeccHRUmalaga: Fin @SEIMC_ 2025, como despedida los 10 trabajos
RT @infeccHRUmalaga: Fin @SEIMC_ 2025, como despedida los 10 trabajos
Fin @SEIMC_ 2025, como despedida los 10 trabajos
2️⃣ BLactamicos en perfusion continua
2.-Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis. The BLING III Randomized Clinical Trial. https://t.co/pT5mfwNsOF
Continuous vs intermittent β-lactam antibiotic infusions in critically ill patients with sepsis. The BLING III randomized clinical trial. Dulhunty et al., 2024 (JAMA) https://t.co/yXLXwB3Uo5
RT @ICUnutrition: ANZICS CTG research (led or contributing) reaching far and wide, presented in Kuwait in the year in review BLING https:/…
RT @ICUnutrition: ANZICS CTG research (led or contributing) reaching far and wide, presented in Kuwait in the year in review BLING https:/…
RT @ICUnutrition: ANZICS CTG research (led or contributing) reaching far and wide, presented in Kuwait in the year in review BLING https:/…
ANZICS CTG research (led or contributing) reaching far and wide, presented in Kuwait in the year in review BLING https://t.co/IShyVWidRT BALANCE https://t.co/AyoAwID9QH @CriticalCareQ8 @anzicsctg @georgeinstitute @NaomiHammond
Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis https://t.co/zElyyTAf0T
Most Viewed JAMA 2024: Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With #Sepsis
RT @JAMA_current: @LRSorce @SebastianPalmqv @NiklasMattsson4 Most Viewed JAMA 2024: Continuous vs Intermittent β-Lactam Antibiotic Infusion…
@LRSorce @SebastianPalmqv @NiklasMattsson4 Most Viewed JAMA 2024: Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With #Sepsis
He presented: Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis: The BLING III Randomized Clinical Trial. #pittccm #upmc #journalclub #ccm #criticalcaremedicine #pittschoolofmedicine #intensivist #criticalcare #pittsburghccm #fellow https://t.co/lsVbNqx7vJ
Original Investigation: Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis | The BLING III Randomized Clinical Trial jamanetwork.com/journals/jam...
RT @JAMA_current: Original Investigation: Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis |…
Original Investigation: Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis | The BLING III Randomized Clinical Trial https://t.co/OgGY97DhG4 https://t.co/0YNWdzwuOO
https://t.co/fexDfoDx7n
#IDSky #PharmSky #MicroSky
Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis: The BLING III Randomized Clinical Trial jamanetwork.com/journals/jam...
Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With SepsisThe BLING III Randomized Clinical Trial https://t.co/PjkUHa88CJ
RT @SCCM_CPP: #CPPPLU Highlights: The BLING III RCT in @JAMA_current by @criticcaredoc et al. found no difference in 90-day mortality but i…
#CPPPLU Highlights: The BLING III RCT in @JAMA_current by @criticcaredoc et al. found no difference in 90-day mortality but improved clinical cure with continuous infusion beta-lactams in ICU patients with sepsis. https://t.co/scAVId0TuD #PharmICU https://t.co/Qr2dQjR4JM
RT @CalderwoodMD: 1/5 Most influential 2024 #abxstewardship papers presented by @tinymuscles at #IDWeek2024: Ongoing evidence supporting pr…
RT @CalderwoodMD: 1/5 Most influential 2024 #abxstewardship papers presented by @tinymuscles at #IDWeek2024: Ongoing evidence supporting pr…
RT @CalderwoodMD: 1/5 Most influential 2024 #abxstewardship papers presented by @tinymuscles at #IDWeek2024: Ongoing evidence supporting pr…
RT @CalderwoodMD: 1/5 Most influential 2024 #abxstewardship papers presented by @tinymuscles at #IDWeek2024: Ongoing evidence supporting pr…
RT @CalderwoodMD: 1/5 Most influential 2024 #abxstewardship papers presented by @tinymuscles at #IDWeek2024: Ongoing evidence supporting pr…
RT @CalderwoodMD: 1/5 Most influential 2024 #abxstewardship papers presented by @tinymuscles at #IDWeek2024: Ongoing evidence supporting pr…
RT @CalderwoodMD: 1/5 Most influential 2024 #abxstewardship papers presented by @tinymuscles at #IDWeek2024: Ongoing evidence supporting pr…
RT @CalderwoodMD: 1/5 Most influential 2024 #abxstewardship papers presented by @tinymuscles at #IDWeek2024: Ongoing evidence supporting pr…
RT @CalderwoodMD: 1/5 Most influential 2024 #abxstewardship papers presented by @tinymuscles at #IDWeek2024: Ongoing evidence supporting pr…
RT @CalderwoodMD: 1/5 Most influential 2024 #abxstewardship papers presented by @tinymuscles at #IDWeek2024: Ongoing evidence supporting pr…
RT @CalderwoodMD: 1/5 Most influential 2024 #abxstewardship papers presented by @tinymuscles at #IDWeek2024: Ongoing evidence supporting pr…
1/5 Most influential 2024 #abxstewardship papers presented by @tinymuscles at #IDWeek2024: Ongoing evidence supporting prolonged/continuous infusion of beta-lactam abx, BUT higher risk of catheter complications & abx side effects. https://t.co/9LXLEmzfjB, https://t.co/CyNyA2TdtA
RT @chemasalas3: Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis https://t.co/Ixx5XcDNNr
Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis https://t.co/Ixx5XcDNNr
RT @intensivecare_c: 敗血症による重症患者へのβラクタム系抗菌薬は持続投与?それとも間欠投与? 90日死亡率に有意差はないものの、持続投与の方が良さそうな傾向。 BLING III trial https://t.co/5q7rKAIlf3
New from JN Learning: Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis https://t.co/HZuBuF8sDh
Ensayo BLING III https://t.co/AGlcEtxR8D
RT @Takashi_Matono: JAMA. 2024;332(8):629-637. 一方で、こちらの大規模RCTでは有益性は示せず… https://t.co/rmQwKC3GWO
JAMA. 2024;332(8):629-637. 一方で、こちらの大規模RCTでは有益性は示せず… https://t.co/rmQwKC3GWO
RT @ESICM:
①Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis: The BLING III Randomized Clinical Trial https://t.co/G6FdKVmey7
RT @JAMA_current: BLING III: In critically ill patients with sepsis, continuous vs intermittent β-lactam antibiotic infusions did not signi…
RT @JAMA_current: BLING III: In critically ill patients with sepsis, continuous vs intermittent β-lactam antibiotic infusions did not signi…
RT @JAMA_current: BLING III: In critically ill patients with sepsis, continuous vs intermittent β-lactam antibiotic infusions did not signi…
RT @JAMA_current: BLING III: In critically ill patients with sepsis, continuous vs intermittent β-lactam antibiotic infusions did not signi…
RT @JAMA_current: BLING III: In critically ill patients with sepsis, continuous vs intermittent β-lactam antibiotic infusions did not signi…
RT @JAMA_current: BLING III: In critically ill patients with sepsis, continuous vs intermittent β-lactam antibiotic infusions did not signi…
RT @JAMA_current: BLING III: In critically ill patients with sepsis, continuous vs intermittent β-lactam antibiotic infusions did not signi…
BLING III: In critically ill patients with sepsis, continuous vs intermittent β-lactam antibiotic infusions did not significantly reduce 90-day mortality. https://t.co/s2wdF1Qg2b https://t.co/luhusWZ7fJ
ICU敗血症患者でPIPC/TAZかMEMPの持続投与は間欠投与に比べて90日後の全死因死亡を減らさず。 一応secondary outcomeの14日後のclinical cureは差ついてるのね。ハードアウトカムで差がつかないならダメなのか、理論と感染症治療的には持続投与のがちょっと良いのか分からん。 https://t.co/YNlFWNCxlB
Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis https://t.co/VSXeLYynAe
New from Ed Hub Infectious Diseases: Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis https://t.co/h8bhh8kNEz
Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis https://t.co/qonWTQZOiD
Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis: The BLING III Randomized Clinical Trial | Critical Care Medicine | JAMA | JAMA Network https://t.co/oGgHqk0UKt
Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis https://t.co/h4Jkzj1fXO
RT @WICSBottomLine: #TBL 455: BLING III - Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients with Sepsis…
RT @WICSBottomLine: #TBL 455: BLING III - Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients with Sepsis…
#TBL 455: BLING III - Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients with Sepsis The BLING III Randomized Clinical Trial https://t.co/T9MxdXkkSX Article by Dalhunty Review by Guo #FOAMed #PharmD https://t.co/Mj7HfOig2x
RT @bryanacotton1: Continuous b-lactam infusion had ⬇️
RT @IcuCast: We talk #BLING3 from #CCR24 and published in @JAMA_current looking at continuous vs intermittent bolus antibiotic dosing of be…
RT @IcuCast: We talk #BLING3 from #CCR24 and published in @JAMA_current looking at continuous vs intermittent bolus antibiotic dosing of be…
RT @IcuCast: We talk #BLING3 from #CCR24 and published in @JAMA_current looking at continuous vs intermittent bolus antibiotic dosing of be…
We talk #BLING3 from #CCR24 and published in @JAMA_current looking at continuous vs intermittent bolus antibiotic dosing of beta lactams. Honored to be joined by @JoannaCCPharmD! BLING3: https://t.co/43Ey5cb3pJ On your fav podcast app: https://t.co/qPyhTM2Rd4 @CritCareReviews
RT @SCCM_CPP: @SCCM @AlyssaGarelli @EskenaziHealth @of_aic #SCCMJC #PharmICU Presenter 2: Nihad Medar, PharmD @nihadmedar99 PGY2 CC @Brigha…
@SCCM @AlyssaGarelli @EskenaziHealth @of_aic #SCCMJC #PharmICU Presenter 2: Nihad Medar, PharmD @nihadmedar99 PGY2 CC @BrighamWomens Continuous vs Intermittent Beta-Lactam Antibiotic Infusions in Critically Ill Patients with Sepsis: The BLING III RCT @JAMA https://t.co/scAVId0TuD
Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis: The BLING III Rand… https://t.co/Yoc1u26KkC βラクタム系抗菌薬の持続vs間歇投与の有意性の報告 90日以内全死因死亡は差が無く副次評価項目のうち臨床的治癒率は、持続の方が良かった。
RT @SCCM_CPP: @SCCM @AlyssaGarelli @EskenaziHealth @of_aic #SCCMJC #PharmICU Presenter 2: Nihad Medar, PharmD @nihadmedar99 PGY2 CC @Brigha…
@SCCM @AlyssaGarelli @EskenaziHealth @of_aic #SCCMJC #PharmICU Presenter 2: Nihad Medar, PharmD @nihadmedar99 PGY2 CC @BrighamWomens Continuous vs Intermittent Beta-Lactam Antibiotic Infusions in Critically Ill Patients with Sepsis: The BLING III RCT @JAMA https://t.co/scAVId0TuD
RT @Takatsuki_GIM: 敗血症に抗菌薬の間欠vs持続 10.1001/jama.2024.9779 過去に複数の間欠vs持続研究あり 今回過去最大規模RCT BLING III P: 重症敗血症 I: β-L (PIPC/TAZ or MEPM)持続 C: 間欠…
RT @Takatsuki_GIM: 敗血症に抗菌薬の間欠vs持続 10.1001/jama.2024.9779 過去に複数の間欠vs持続研究あり 今回過去最大規模RCT BLING III P: 重症敗血症 I: β-L (PIPC/TAZ or MEPM)持続 C: 間欠…
RT @Takatsuki_GIM: 敗血症に抗菌薬の間欠vs持続 10.1001/jama.2024.9779 過去に複数の間欠vs持続研究あり 今回過去最大規模RCT BLING III P: 重症敗血症 I: β-L (PIPC/TAZ or MEPM)持続 C: 間欠…
RT @Takatsuki_GIM: 敗血症に抗菌薬の間欠vs持続 10.1001/jama.2024.9779 過去に複数の間欠vs持続研究あり 今回過去最大規模RCT BLING III P: 重症敗血症 I: β-L (PIPC/TAZ or MEPM)持続 C: 間欠…
RT @Takatsuki_GIM: 敗血症に抗菌薬の間欠vs持続 10.1001/jama.2024.9779 過去に複数の間欠vs持続研究あり 今回過去最大規模RCT BLING III P: 重症敗血症 I: β-L (PIPC/TAZ or MEPM)持続 C: 間欠…
RT @Takatsuki_GIM: 敗血症に抗菌薬の間欠vs持続 10.1001/jama.2024.9779 過去に複数の間欠vs持続研究あり 今回過去最大規模RCT BLING III P: 重症敗血症 I: β-L (PIPC/TAZ or MEPM)持続 C: 間欠…
RT @Takatsuki_GIM: 敗血症に抗菌薬の間欠vs持続 10.1001/jama.2024.9779 過去に複数の間欠vs持続研究あり 今回過去最大規模RCT BLING III P: 重症敗血症 I: β-L (PIPC/TAZ or MEPM)持続 C: 間欠…
敗血症に抗菌薬の間欠vs持続 10.1001/jama.2024.9779 過去に複数の間欠vs持続研究あり 今回過去最大規模RCT BLING III P: 重症敗血症 I: β-L (PIPC/TAZ or MEPM)持続 C: 間欠 O: 90死亡、治癒 結果:死亡有意差なし、持続で臨床的治癒率が高い これまでの試験を統合したメタ解析を見たいです https://t.co/xMuioVW8Gt
RT @KatiaDonadello: Here we are for this 2nd day #EUROASIA2024 conference. @criticcaredoc stricking on beta-lactam continuous infusion in c…
RT @CritCareReviews: The BLING III trialists summarise their presentation from CCR24 this morning Simultaneously published in @JAMA_curren…
Reference doi (
@ADAlthousePhD @DavidHarrison80 @gushamilton @statsepi @jd_wilko Especially in case you do a whoopsu and make the unadjusted analysis your primary outcome and miss the magic p value Another excellent, excellent teaching case https://t.co/z6PPvT7eoU
RT @infeccHRUmalaga: Después dl MERCY(Meropenem en pacientes críticos)en @JAMA_current otro ensayo clínico
RT @ABsteward:
RT @KatiaDonadello: Here we are for this 2nd day #EUROASIA2024 conference. @criticcaredoc stricking on beta-lactam continuous infusion in c…
RT @KatiaDonadello: Here we are for this 2nd day #EUROASIA2024 conference. @criticcaredoc stricking on beta-lactam continuous infusion in c…
RT @KatiaDonadello: Here we are for this 2nd day #EUROASIA2024 conference. @criticcaredoc stricking on beta-lactam continuous infusion in c…
RT @KatiaDonadello: Here we are for this 2nd day #EUROASIA2024 conference. @criticcaredoc stricking on beta-lactam continuous infusion in c…
RT @KatiaDonadello: Here we are for this 2nd day #EUROASIA2024 conference. @criticcaredoc stricking on beta-lactam continuous infusion in c…
Here we are for this 2nd day #EUROASIA2024 conference. @criticcaredoc stricking on beta-lactam continuous infusion in critically ill patients, from PK/PD to clinical practice. Latest research 1. BLING III RCT continuous vs intermittent infusion MER/PIPTAZ https://t.co/cj2LYvDXfE https://t.co/oo66MYOj7n
Trend up+39: Dulhunty JM, ..., Bling III Study Investigators (JAMA) __Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis: The BLING III Randomized Clinical Trial__ https://t.co/yqsiABY2hd
RT @ABsteward:
RT @ABsteward:
Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis https://t.co/6lZ8cFocps https://t.co/eETZ1mn549
RT @pinacol: 【RCT】敗血症患者へのピペラシリン-タゾバクタムまたはメロペネムの持続注入は、間欠注入と比較して、90日死亡率を改善させなかった。 #ペ読 https://t.co/50mxrtURFp
https://t.co/inhfGJ9uB2 ICUにおいて敗血症患者に対し抗生剤(PIPC/TAZorMEPM)の持続投与or間欠投与で90日死亡率が変わるかを調べたRCT 結果は両群間で差はなかった(24.9vs26.9%;差:-1.9[-4.9to1.1]%)臨床的治癒率は持続群で良かった(55.7vs50.0%;差:5.7[2.4-9.1]%) #当麻_感染
RT @ABsteward:
Trending on PubMed: Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis: The BLING III Randomized Clinical Trial. https://t.co/GEykf0IHZa
Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis https://t.co/n1VyAQtGS5
@ISICEM Critical Care Input Continuous vs Intermittent β-Lactam #Antibiotic Infusions in Critically Ill Patients With #Sepsis: The BLING III Randomized Clinical Trial #ISICEMelearning #Meded @JAMANetworkOpen #CriticalCare
RT @CritCareReviews: The BLING III trialists summarise their presentation from CCR24 this morning Simultaneously published in @JAMA_curren…
RT @MMarmiere: 3/ #BLINGIII
RT @ndanmontero: Enfoque a la infusión IV continua de beta lactámicos en pacientes en el espectro de la sepsis. Continuous vs Intermittent…
RT @CritCareReviews: The BLING III trialists summarise their presentation from CCR24 this morning Simultaneously published in @JAMA_curren…
RT @MMarmiere: 3/ #BLINGIII
3/ #BLINGIII
【RCT】敗血症患者へのピペラシリン-タゾバクタムまたはメロペネムの持続注入は、間欠注入と比較して、90日死亡率を改善させなかった。 #ペ読 https://t.co/50mxrtURFp
RT @infeccHRUmalaga: Después dl MERCY(Meropenem en pacientes críticos)en @JAMA_current otro ensayo clínico
#REVISE 挿管中のPPI投与で死亡率変わらず、上部消化管出血減らす https://t.co/gZyrXJiSCD JAMA #BLING III 敗血症へβラクタム系持続で90日死亡率変わらず https://t.co/8BAQNjMyTt #DEFENDER 循環呼吸腎不全患者にフォシーガ10㎎で臨床転帰変わらず https://t.co/TnZL0HRf4S
https://t.co/nSszLDLe4I Intermittent vs continous infusion of Beta-lactum antibiotics and mortality @JAMA_current https://t.co/L972jXdWXm
RT @ABsteward:
RT @ndanmontero: Enfoque a la infusión IV continua de beta lactámicos en pacientes en el espectro de la sepsis. Continuous vs Intermittent…
Enfoque a la infusión IV continua de beta lactámicos en pacientes en el espectro de la sepsis. Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis JAMA June 12, 2024. https://t.co/Udxf1VJgni
Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis https://t.co/g08oJ1SSYw
@ISICEM Critical Care Input Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With #Sepsis The BLING III Randomized Clinical Trial #ISICEMelearning @JAMANetworkOpen #Meded https://t.co/Lw97JTSneV https://t.co/RXftosA6JE
Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis #science #publication #research #publications https://t.co/RYAT9JBFq2
RT @carpe_diem0820: Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis BLING III 試験において、βラクタム…
RT @PROA_maran: Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis https://t.co/ByNyXaFpOe
RT @carpe_diem0820: Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis BLING III 試験において、βラクタム…
Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis BLING III 試験において、βラクタム系抗菌薬の持続点滴と間欠点滴が、重度の敗血症患者の 90 日死亡率に及ぼす影響を評価された。 104の施設のICU で 7,031 https://t.co/0Di9psRsTx
RT @accpinfdprn: BLING III is out!
RT @PROA_maran: Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis https://t.co/ByNyXaFpOe
RT @PROA_maran: Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis https://t.co/ByNyXaFpOe
Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis https://t.co/3MoXZ7X8rX
RT @CarlosdelRio7: Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis @JAMA_current https://t…
RT @accpinfdprn: BLING III is out!
RT @accpinfdprn: BLING III is out!
RT @accpinfdprn: BLING III is out!
RT @bryanacotton1: Continuous b-lactam infusion had ⬇️
RT @accpinfdprn: BLING III is out!
RT @accpinfdprn: BLING III is out!
RT @petita_libelula: Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis https://t.co/eBP9W58UoY
RT @accpinfdprn: BLING III is out!
RT @accpinfdprn: BLING III is out!
BLING III is out!
RT @PROA_maran: Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis https://t.co/ByNyXaFpOe
Continuous b-lactam infusion had ⬇️
RT @JAMA_current: @jasonroberts_pk @PreetiNMalani Read the Original Investigation “Continuous vs Intermittent β-Lactam Antibiotic Infusions…
RT @PROA_maran: Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis https://t.co/ByNyXaFpOe
RT @CarlosdelRio7: Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis @JAMA_current https://t…
RT @PROA_maran: Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis https://t.co/ByNyXaFpOe
Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis @JAMA_current https://t.co/0rfZOeaz5v "In critically ill patients with sepsis, continuous vs intermittent β-lactam antibiotic infusions did not significantly reduce 90-day mortality."
Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis https://t.co/MOniOKVqan
RT @PROA_maran: Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis https://t.co/ByNyXaFpOe
@jasonroberts_pk @PreetiNMalani Read the Original Investigation “Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis.” https://t.co/McXAsI3yEo
RT @PROA_maran: Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis https://t.co/ByNyXaFpOe
RT @PROA_maran: Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis https://t.co/ByNyXaFpOe
Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis https://t.co/eBP9W58UoY
RT @PROA_maran: Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis https://t.co/ByNyXaFpOe
RT @PROA_maran: Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis https://t.co/ByNyXaFpOe
Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis https://t.co/ByNyXaFpOe
Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis: The BLING III Randomized Clinical Trial | Critical Care Medicine | JAMA | JAMA Network https://t.co/kKTIrm448r
⏱️⚗️Infusiones prolongadas vs. intermitentes de β-lactámicos en adultos con sepsis o shock séptico
⏱️⚗️Infusiones prolongadas vs. intermitentes de β-lactámicos en adultos con sepsis o shock séptico
Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis: The BLING III Randomized Clinical Trial - PubMed https://t.co/GhJg6ce24t #cdi #cdiff
Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis: The BLING III Randomized Clinical Trial | Critical Care Medicine | JAMA | JAMA Network https://t.co/CwcGtz31Rt
J